Lyophilised powder · 99%+ documented HPLC
Synthetic pentadecapeptide derived from a gastric protein, widely studied in tissue-repair and cytoprotection models.
$59.99per 10mg vial
Figures are structural data from our specification and certificates, or are drawn from published third-party literature about the compound, and are provided for orientation only. Nothing here is a claim about what this material does. Supplied for laboratory research use only.
BPC-157 is a synthetic pentadecapeptide. A chain of fifteen amino acids corresponding to a partial sequence of Body Protection Compound, a protein identified in gastric juice. It is supplied lyophilised as a stable reference standard and is one of the most widely requested peptides in preclinical tissue-repair literature.
C62H98N16O22 · composition, not conformation
Signalling pathways examined in preclinical models. Descriptive of published research directions, not claims of effect.
Preclinical work has examined BPC-157 in the context of vascular endothelial growth factor signalling and the formation of new microvasculature in injured tissue models.
A body of in-vitro work has looked at BPC-157 alongside growth hormone receptor expression in fibroblast and tendon-derived cell cultures.
Much of the original literature characterised the parent compound in gastrointestinal mucosal models, where cytoprotective behaviour was the primary observation.
Frequently used in preclinical models examining connective tissue repair, collagen organisation, and fibroblast behaviour.
The compound's original characterisation was in gastric and intestinal models, which remains an active area of published work.
Investigated in peripheral nerve injury preparations and in relation to neurotrophic signalling markers.
Examined in vessel-formation and endothelial-migration assays alongside angiogenic markers.
Reference class characteristics for orientation. Half-life figures are typical literature values, not lot measurements.
| Compound | Receptor class | Typical half-life | Note |
|---|---|---|---|
| BPC-157 | Pentadecapeptide | Short | Cytoprotection |
| TB-500 | Tβ4 fragment | Longer | Actin regulation |
| GHK-Cu | Tripeptide-Cu | Short | ECM remodelling |
A multi-axis orientation profile. Relative, not absolute affinity data.
Axes are normalised 0 to 100 for comparison. These are directional summaries of published class data, not measured binding constants for this lot.
A relative plasma-concentration model over time, normalised so the peak reads 100.
Illustrative. A typical profile for the compound class, not a measured result for this product.
Milestones in the study of this compound class.
The BPC sequence is identified in gastric-juice protein research.
Angiogenesis and tendon-fibroblast models published.
Gastric mucosal and nitric-oxide pathway mechanisms characterised.
Broad adoption as a reference peptide in tissue research.
Every lot is documented by an independent laboratory. The newest lot appears first.
| Lot | Reported | Size | HPLC | Laboratory | Certificate |
|---|---|---|---|---|---|
| 2FRBRG | 29 May 2026 | 10mg | 99.51% | Freedom Diagnostics | View |
| BPC11182025-J | 21 Nov 2025 | 10mg | 99.247% | Freedom Diagnostics | View |
| WQ988T | 11 Mar 2026 | 10mg | 99.665% | Freedom Diagnostics | View |
99.51%
HPLC purity
The signed PDF is the full certificate. The accession and search code above resolve the same record at the laboratory.
HPLC purity
RP-HPLC, 214 nm
Identity
LC-MS
Lot 2FRBRG
A synthetic fifteen–amino-acid peptide corresponding to a partial sequence of Body Protection Compound, a protein originally isolated from gastric juice. It is one of the most-cited cytoprotection and tissue-repair research peptides, studied across angiogenesis, tendon-fibroblast and gut-protection models. Supplied lyophilised as an analytical reference standard.
No. BPC-157 is not an approved drug and has not been evaluated by the FDA for any use. It is sold here strictly as a research reference material and is not intended for human or veterinary consumption.
This material is supplied as a reference standard for in-vitro laboratory research only. It has not been evaluated by the FDA, is not a drug, and is not intended for human or veterinary use. Handling should follow your institution's chemical hygiene plan, including appropriate PPE and documented disposal.
Each lot is assayed by reverse-phase HPLC for purity and by LC-MS for identity confirmation, at an independent laboratory named on the certificate. The full chromatogram is published with the lot, not just the headline figure.
No. They are unrelated sequences studied for different parts of tissue repair. BPC-157 is a fifteen-residue fragment of a gastric protein, researched for angiogenesis and cytoprotection. TB-500 is a seven-residue fragment of thymosin beta-4, researched for actin regulation and cell migration. They are often studied side by side, which is why they are frequently confused.
Yes — one per lot, signed by the testing laboratory, with the lot number, the HPLC result, identity confirmation and the measured net peptide content. All three are published in the COA library, including for lots no longer in stock.
A single 10mg vial.
GEPPPGKPADDAGLV. Fifteen residues, corresponding to a partial sequence of Body Protection Compound found in human gastric juice.
Store the sealed vial at −20°C for long-term stability and 2–8°C for short-term handling. Protect from light and avoid repeated freeze-thaw cycles. Compound-specific stability data is printed on the certificate of analysis supplied with the lot.
This material is supplied as a reference standard for in-vitro laboratory research only. It has not been evaluated by the FDA, is not a drug, and is not intended for human or veterinary use. Handling should follow your institution's chemical hygiene plan, including appropriate PPE and documented disposal.
Independent published research relating to this compound. Listed for reference; Serviam Bio Labs is not affiliated with these authors and makes no claims based on their findings.
The promoting effect of pentadecapeptide BPC 157 on tendon fibroblast migration and healing
Chang CH et al. · 2011 · Journal of Applied Physiology
repairBPC 157 and the VEGFR2-Akt-eNOS angiogenic pathway
Hsieh MJ et al. · 2017 · Journal of Molecular Medicine
mechanismStable gastric pentadecapeptide BPC 157 and gastrointestinal cytoprotection
Sikiric P et al. · 2018 · Current Pharmaceutical Design
mechanismStable gastric pentadecapeptide BPC 157 and vascular occlusion
Sikiric P et al. · 2019 · Current Neuropharmacology
vascularBrain-gut axis and pentadecapeptide BPC 157
Sikiric P et al. · 2016 · Current Neuropharmacology
neuroThe full reference entry: molecular data, the mechanisms described in the literature, what the research covers, the specification and the papers behind it.
For laboratory research use only. All compounds listed on this site are sold strictly as reference materials for in-vitro laboratory research conducted by qualified professionals. They are not drugs, foods, cosmetics, or medical devices. They are not intended for human or veterinary consumption, therapeutic use, diagnostic application, or any in-vivo use whatsoever. These statements have not been evaluated by the Food and Drug Administration. By purchasing, you affirm that you are a qualified researcher and that you will comply with all applicable institutional, local, state and federal regulations governing the handling of research chemicals.
